Navigation Links
Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
Date:5/9/2008

RICHMOND, Calif., May 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 7:40 p.m. (ET) on Tuesday, May 13, 2008 at the Bank of America Healthcare Conference in Las Vegas.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFTM) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNTM) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. Inaugural Kirkham Gold Medal presented to expert on soil physics
2. Reflecting on the social implications of human genetics research -- past, present and future
3. 2008 Signature Genomic Laboratories Travel Award presented
4. Womens health-related scientific findings presented by University of Pittsburgh researchers
5. Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
6. Pioneers in small RNA research to present at UD symposium, April 16
7. Climate change in the Baltic Sea basin -- past, present and future
8. Internationally recognized experts presents a complete overview on hydroecology and ecohydrology
9. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
10. Present-day species of piranha result from a marine incursion into the Amazon Basin
11. New book presents methods to poke and prod individual molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... PUNE, India , May 3, 2016 ... Type (DNA Chip (Genomics, Drug Discovery, Gene ... Chips), End user (Academics Institutes, Diagnostics Centers), ... 2020" published by MarketsandMarkets, the market is ... 2020 from USD 7.63 Billion in 2015, ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... Playbook™ enterprise talent development, skill-building and compliance training platform on mobile devices, ... training course: Overview of Regulatory Requirements for Medical Devices. The course is essential ...
(Date:5/3/2016)... MA (PRWEB) , ... May 03, 2016 , ... In ... number 25 out of the state’s 76 fastest-growing private companies; a small percentage of ... Massachusetts, and ranked organizations on the percent change in revenue from 2012 to 2015. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading ... 2016 on May 31st and June 1st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
Breaking Biology Technology: